Sign up
Pharma Capital
Why invest in NRT?

Novogen: Access latest PPT from Proactive's CEO Sessions

Dr James Garner talked clinical-stage programs with investors.
Novogen: Access latest PPT from Proactive's CEO Sessions
Dr James Garner, chief executive officer, Novogen

Novogen’s (ASX:NRT, NASDAQ:NVGN) chief executive officer, Dr James Garner, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April.

Novogen is an emerging oncology drug developer with two clinical-stage programs.

The company's value proposition is to partner with big pharma for late-stage development to bring to market.


Register here to be notified of future NRT Company articles
View full NRT profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.